vs
Steris（STE）与Stryker Corporation（SYK）财务数据对比。点击上方公司名可切换其他公司
Stryker Corporation的季度营收约是Steris的4.8倍（$7.2B vs $1.5B），Steris净利率更高（12.9% vs 11.8%，领先1.1%），Stryker Corporation同比增速更快（11.4% vs 9.2%），Stryker Corporation自由现金流更多（$1.9B vs $199.5M），过去两年Stryker Corporation的营收复合增速更高（16.9% vs 15.8%）
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
斯特赖克是一款八轮装甲战车，衍生自加拿大LAV III步兵战车，而后者源自瑞士莫瓦格食人鱼系列装甲车。该型战车由加拿大通用动力陆地系统公司为美国陆军生产，制造工厂位于安大略省伦敦市。它默认采用8×4四轮驱动，可切换为8×8全轮驱动模式。
STE vs SYK — 直观对比
营收规模更大
SYK
是对方的4.8倍
$1.5B
营收增速更快
SYK
高出2.3%
9.2%
净利率更高
STE
高出1.1%
11.8%
自由现金流更多
SYK
多$1.7B
$199.5M
两年增速更快
SYK
近两年复合增速
15.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $7.2B |
| 净利润 | $192.9M | $849.0M |
| 毛利率 | 43.8% | 64.5% |
| 营业利润率 | 18.3% | 25.2% |
| 净利率 | 12.9% | 11.8% |
| 营收同比 | 9.2% | 11.4% |
| 净利润同比 | 11.2% | 55.5% |
| 每股收益（稀释后） | $1.96 | $2.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收STESYK
| Q4 25 | $1.5B | $7.2B | ||
| Q3 25 | $1.5B | $6.1B | ||
| Q2 25 | $1.4B | $6.0B | ||
| Q1 25 | $1.5B | $5.9B | ||
| Q4 24 | $1.4B | $6.4B | ||
| Q3 24 | $1.3B | $5.5B | ||
| Q2 24 | $1.3B | $5.4B | ||
| Q1 24 | $1.1B | $5.2B |
净利润STESYK
| Q4 25 | $192.9M | $849.0M | ||
| Q3 25 | $191.9M | $859.0M | ||
| Q2 25 | $177.4M | $884.0M | ||
| Q1 25 | $145.7M | $654.0M | ||
| Q4 24 | $173.5M | $546.0M | ||
| Q3 24 | $150.0M | $834.0M | ||
| Q2 24 | $145.4M | $825.0M | ||
| Q1 24 | $-1.4M | $788.0M |
毛利率STESYK
| Q4 25 | 43.8% | 64.5% | ||
| Q3 25 | 44.2% | 63.6% | ||
| Q2 25 | 45.1% | 63.8% | ||
| Q1 25 | 43.3% | 63.8% | ||
| Q4 24 | 44.5% | 64.9% | ||
| Q3 24 | 43.6% | 64.0% | ||
| Q2 24 | 44.7% | 63.0% | ||
| Q1 24 | 40.2% | 63.6% |
营业利润率STESYK
| Q4 25 | 18.3% | 25.2% | ||
| Q3 25 | 18.2% | 18.7% | ||
| Q2 25 | 17.7% | 18.5% | ||
| Q1 25 | 14.6% | 14.3% | ||
| Q4 24 | 17.9% | 9.0% | ||
| Q3 24 | 16.5% | 19.7% | ||
| Q2 24 | 14.5% | 19.4% | ||
| Q1 24 | 22.0% | 18.5% |
净利率STESYK
| Q4 25 | 12.9% | 11.8% | ||
| Q3 25 | 13.1% | 14.2% | ||
| Q2 25 | 12.8% | 14.7% | ||
| Q1 25 | 9.8% | 11.1% | ||
| Q4 24 | 12.7% | 8.5% | ||
| Q3 24 | 11.3% | 15.2% | ||
| Q2 24 | 11.4% | 15.2% | ||
| Q1 24 | -0.1% | 15.0% |
每股收益（稀释后）STESYK
| Q4 25 | $1.96 | $2.20 | ||
| Q3 25 | $1.94 | $2.22 | ||
| Q2 25 | $1.79 | $2.29 | ||
| Q1 25 | $1.48 | $1.69 | ||
| Q4 24 | $1.75 | $1.41 | ||
| Q3 24 | $1.51 | $2.16 | ||
| Q2 24 | $1.46 | $2.14 | ||
| Q1 24 | $-0.02 | $2.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $423.7M | $4.0B |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $7.2B | $22.4B |
| 总资产 | $10.6B | $47.8B |
| 负债/权益比越低杠杆越低 | 0.27× | — |
8季度趋势，按日历期对齐
现金及短期投资STESYK
| Q4 25 | $423.7M | $4.0B | ||
| Q3 25 | $319.2M | $3.3B | ||
| Q2 25 | $279.7M | $2.4B | ||
| Q1 25 | $171.7M | $2.3B | ||
| Q4 24 | $155.2M | $3.7B | ||
| Q3 24 | $172.2M | $3.9B | ||
| Q2 24 | $198.3M | $1.9B | ||
| Q1 24 | $207.0M | $2.3B |
总债务STESYK
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $3.1B | — |
股东权益STESYK
| Q4 25 | $7.2B | $22.4B | ||
| Q3 25 | $7.0B | $21.8B | ||
| Q2 25 | $7.0B | $21.2B | ||
| Q1 25 | $6.6B | $20.9B | ||
| Q4 24 | $6.4B | $20.6B | ||
| Q3 24 | $6.6B | $20.1B | ||
| Q2 24 | $6.4B | $19.8B | ||
| Q1 24 | $6.3B | $19.2B |
总资产STESYK
| Q4 25 | $10.6B | $47.8B | ||
| Q3 25 | $10.4B | $47.1B | ||
| Q2 25 | $10.4B | $46.3B | ||
| Q1 25 | $10.1B | $46.0B | ||
| Q4 24 | $10.0B | $43.0B | ||
| Q3 24 | $10.2B | $43.8B | ||
| Q2 24 | $10.1B | $39.1B | ||
| Q1 24 | $11.1B | $39.4B |
负债/权益比STESYK
| Q4 25 | 0.27× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $298.2M | $2.1B |
| 自由现金流经营现金流 - 资本支出 | $199.5M | $1.9B |
| 自由现金流率自由现金流/营收 | 13.3% | 26.1% |
| 资本支出强度资本支出/营收 | 6.6% | 3.7% |
| 现金转化率经营现金流/净利润 | 1.55× | 2.52× |
| 过去12个月自由现金流最近4个季度 | $917.1M | $4.3B |
8季度趋势，按日历期对齐
经营现金流STESYK
| Q4 25 | $298.2M | $2.1B | ||
| Q3 25 | $287.8M | $1.5B | ||
| Q2 25 | $420.0M | $1.1B | ||
| Q1 25 | $260.8M | $250.0M | ||
| Q4 24 | $332.8M | $1.9B | ||
| Q3 24 | $250.7M | $1.5B | ||
| Q2 24 | $303.7M | $633.0M | ||
| Q1 24 | $254.8M | $204.0M |
自由现金流STESYK
| Q4 25 | $199.5M | $1.9B | ||
| Q3 25 | $201.3M | $1.4B | ||
| Q2 25 | $326.4M | $928.0M | ||
| Q1 25 | $189.9M | $127.0M | ||
| Q4 24 | $243.6M | $1.7B | ||
| Q3 24 | $148.8M | $1.3B | ||
| Q2 24 | $195.7M | $481.0M | ||
| Q1 24 | $163.3M | $37.0M |
自由现金流率STESYK
| Q4 25 | 13.3% | 26.1% | ||
| Q3 25 | 13.8% | 22.3% | ||
| Q2 25 | 23.5% | 15.4% | ||
| Q1 25 | 12.8% | 2.2% | ||
| Q4 24 | 17.8% | 25.9% | ||
| Q3 24 | 11.2% | 23.7% | ||
| Q2 24 | 15.3% | 8.9% | ||
| Q1 24 | 14.6% | 0.7% |
资本支出强度STESYK
| Q4 25 | 6.6% | 3.7% | ||
| Q3 25 | 5.9% | 3.1% | ||
| Q2 25 | 6.7% | 3.0% | ||
| Q1 25 | 4.8% | 2.1% | ||
| Q4 24 | 6.5% | 4.1% | ||
| Q3 24 | 7.7% | 3.1% | ||
| Q2 24 | 8.4% | 2.8% | ||
| Q1 24 | 8.2% | 3.2% |
现金转化率STESYK
| Q4 25 | 1.55× | 2.52× | ||
| Q3 25 | 1.50× | 1.79× | ||
| Q2 25 | 2.37× | 1.26× | ||
| Q1 25 | 1.79× | 0.38× | ||
| Q4 24 | 1.92× | 3.54× | ||
| Q3 24 | 1.67× | 1.77× | ||
| Q2 24 | 2.09× | 0.77× | ||
| Q1 24 | — | 0.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
SYK
| Medical | $1.3B | 18% |
| Endoscopy | $1.1B | 16% |
| Traumaand Extremities | $1.1B | 15% |
| Instruments | $925.0M | 13% |
| Knees | $749.0M | 10% |
| Neuro Cranial | $669.0M | 9% |
| Neurovascular | $539.0M | 8% |
| Hips | $499.0M | 7% |
| Other Orthopaedics | $267.0M | 4% |
| Spine | $8.0M | 0% |
